Petri Dish Tumor Test
News Jun 15, 2015
The advance could mean a giant step forward in efforts to tailor medical treatment plans to individual patients.
Led by Shigeki Miyamoto, a professor of oncology at UW-Madison, and David Beebe, the John D. MacArthur Professor and Claude Bernard professor of biomedical engineering at UW-Madison.
"We're taking the first steps toward mimicking the body in a dish," Beebe says.
Much of the research was led by Chorom Pak, who previously was a graduate student working in Miyamoto's lab.
Pak and Edmond Young (now at the University of Toronto) and the other researchers produced an assay, or testing process, which involves co-culturing multiple myeloma tumor cells with their surrounding nontumor cells, all from the same patient, in a microscale petri dish. The researchers then treated the tumor cells with bortezomib, a drug commonly used in multiple myeloma therapy. And after only three days, the researchers could determine whether the drug was effective — or not.
They compared the results of their ex vivo tests with the success or failure rates of actual patients who had received the drug — and an unprecedented 100 percent of the ex vivo test results matched the results of the patients.
Multiple myeloma is a universally fatal cancer. Rising in the blood marrow due to an accumulation of abnormal, or cancerous, plasma cells, myeloma is treatable but incurable.
"The median survival rate has improved, but is only about five to seven years," Pak says.
The new assay could save many multiple myeloma cancer patients the psychological stress of having to try multiple drugs until they find the most effective one. The assay reduces clinicians' need for this trial-and-error approach while treating a patient, and it also lowers the cost of treatment.
The fundamental idea behind the research was to focus on everything surrounding a tumor, not just the tumor itself. These surroundings can include bone marrow stromal cells, macrophages and other immune cells, all of which represent an integral part of the tumor's environment. By including these components in a microfluidic petri dish — a device developed by Beebe and Miyamoto's lab a few years ago — the researchers' ability to accurately gauge results increased dramatically.
Beebe says scaling down the testing environment in the group's research is akin to moving from a lake to a bathtub: While the huge area of a standard-sized petri dish dilutes all the extra cells, the microscale petri dish the team used allows cancer cells to continue interacting with their usual surroundings, but outside of the body.
The researchers essentially created a miniaturized external model of an individual's cancer, says Pak.
She has founded a service-based company called Lynx Biosciences based on these findings, and the company was recently a finalist in the 2015 Wisconsin Governor's Business Plan Contest. Pak and fellow researchers are looking to conduct a prospective trial, which, instead of simply matching the results of patients with that of the ex vivo tests, will actually use the ex vivo tests to identify responsive and nonresponsive patients. In addition, they are starting to consider what this discovery means for other cancer types and other drugs.
The researchers' results could have interesting and wide-ranging implications for the future of cancer treatment and therapy, although their work is far from over.
"This is only one type of cancer, one particular drug, and we're a long way from implementing this and helping patients in a widespread way," Beebe says. "But it's happening. This is an exciting time in this area, and we're definitely going to see more of this."
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE